Clinical Trials Logo

Citation(s)

A Phase I Dose-Ranging Safety Study Using Intranodal Delivery of a Plasmid DNA (Synchrotope TA2M) in Adult Stage IV Melanoma Patients

Details for clinical trial NCT00023647